News Archive

According to a recent report from CBRE, Chicago ranks No. 6 for job growth out of the Top 25 life sciences markets in the U.S. To establish itself as a prominent hub on par with the coastal life sciences clusters in Boston and San Francisco, Chicago needs to enhance its offering in the areas of funding, talent, real estate and infrastructure. While the city has made many positive strides toward becoming a life sciences destination, there are four key steps city and state leaders can take to accelerate this process.

Image: https://www.pexels.com/photo/architectural-photography-of-tunnel-2088233/

Apply Now for Our 2023 Programs!

Applications for our three different Innovator programs – MedTech Innovator US, MedTech Innovator Asia Pacific, and BioTools Innovator – are now open. Read below to learn which program is right for you and apply today.

Companies do not have to relocate, and there is no equity required or fee for participation. The application deadline for all programs is January 31, 2023.

Image: https://thelaunchport.com

Emergent BioSolutions is looking to make progress with its chikungunya vaccine and has received a $10 million US government grant to help it along.

Emergent announced that it has been handed a research award from the Department of Defense Congressional Directed Medical Research Programs to evaluate the efficacy of its single-dose chikungunya virus vaccine candidate.

The coronavirus pandemic has underlined the value of clearly communicating scientific data, public health guidance and risk factors amidst uncertainty. On Tuesday, Dec. 6 at 9:00 a.m. ET, join Washington Post Live for a series of conversations with Francis S. Collins, former director of the National Institutes of Health, Katrine Wallace, an epidemiologist from the University of Illinois Chicago School of Public Health, and Kurt Newman, president and CEO of Children’s National Hospital, about strengthening trust in science across society, countering misinformation and navigating heightened political divisions.

Image: https://www.washingtonpost.com/

October 6, 2022 – Now accepting Letters of Intent (LOI) for Grant Round 14 

Dec 7, 2022   5:00 PM EDT  Deadline to submit LOI for consideration in Grant Round 14

December 16, 2022   Invitation to submit a full application will be sent to Applicant Teams whose LOI meets funding criteria

February 2, 2023  5:00 PM Eastern  Deadline to submit full application for Grant Round 14

February 24, 2023  Invitation to present proposal in person to our Project Management and Oversight Panel (PMOP) will be sent to the top 8 applicant teams as determined by scoring and ranking of applications

Week of March 13, 2023  Proposal Presentations 

Week of March 20, 2023 Virginia Board of Directors final funding decision for Grant Round 14 March 2023  Grant Round 14 Awardees announced

Hello everybody, Wizbiosolutions team is MEDICA in Dusseldorf. We are in Hall 1, E18 now. Please come to visit our booth and discuss about new technology that we have. We are all welcomeing you.

Image: https://www.linkedin.com

The Johns Hopkins University researchers behind two of Baltimore’s most successful biotech firms have founded a new company that has now raised $56 million to create a new diagnostic tool for cancer.

Haystack Oncology plans to use the funding from its series A round to kickstart a move into a large lab inside of City Garage in Port Covington, which was recently renamed Baltimore Peninsula. The company also plans to invest in more clinical trials to get additional data to support the effectiveness of Haystack’s cancer detection blood test. The 50-person company, currently based at Hopkins’ FastForwardU, plans to have a commercial launch in 2023.

From New York to Paris and London, life sciences companies are being drawn to parts of town often more synonymous with financial services. In London, the Canary Wharf Group and Kadans Science Partner are jointly developing Europe’s largest commercial laboratory building. Life science organization Genomics England will move in later this year, joined by a mix of startups, academics, clinicians and established pharmaceutical companies.

Merck KGaA, Darmstadt, Germany, a leading science and technology company, invests more than € 290 million in its biosafety testing capacity at Rockville, Maryland, USA. This will significantly increase the company’s ability to conduct biosafety testing and analytical development services. Biosafety testing and analytical development are critical and fundamental requirements of the drug development and commercialization process to ensure the safety of medicines. Global demand for these services is growing at a double-digit rate.

A few of BioBuzz’s favorite stories from late summer/early fall Over the past several months, life sciences companies across the BioHealth Capital Region showcased their innovative capabilities and pipeline development program. BioBuzz takes a look back at five key events that took place in the third quarter.

BioFactura Moves Forward with Stelara Biosimilar

Frederick, Maryland-based BioFactura is beginning to see the fruits of its labors with the development of ustekinumab (BFI-751), its biosimilar for Janssen’s Stelara. In October, the company announced Phase 1 data that showed pharmacokinetic comparability to the comparison drug.

The company also reported there were no marked differences in the safety and tolerability profile for subjects receiving ustekinumab. BioFactura intends to conduct a confirmatory safety and efficacy study in patients to pave the way for global registration.

Image: https://biobuzz.io/